The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation by Markus, PM et al.
/ c).. '7C( 
The Effect of Cyclosporine, Rapamycin and FK 506 the Survival 
Following Allogeneic Bone Marrow Transplantation 
P.M. Markus, X. Cai, G. Selvaggi, M. Cooper, J. Hamaha, J.J. Fung, and T.E. Starzt 
WE have previously reponed that treatment with FK 506 and cyclosporine (Cy A) are effective in revers-
ing established acute graft-versus-host disease (GVHD) in 
an allogeneic rat model. 1 In clinical bone marrow trans-
plantation, however, recovery from GVHD has not nec-
essarily been associated with prolongation of survival. 2.3 
Therefore. we were interested in comparing the immuno-
suppressive agents, CyA, rapamycin (RPM). and FK 506, 
in respect to survival after allogeneic bone marrow and 
spleen ceU transplantation IBMSPTXl. 
MATERIALS AND METHODS 
Induction of Acute GVHD 
A total of 60 x I W bone marrow and 30 x I W spleen cells from 
ACI donors were infused IV 2 hours after Lewis (LEW) reCipients 
had been exposed to 1000 rad total body irradiation (TBll. 
Animals were assessed for clinical signs of GVHD on a daily 
basis. GYHD was diagnosed when at least three of the following 
signs were present: erythematous ear. hyperkeratosis of the 
footpad, dermatitis, weight loss, unkempt appearance, and diar-
rhea. 
Immunosuppression 
CyA was obtained from Sandoz Pharmaceuticals (Hanover. NI) 
and dissolved in intralipid. Rapamycin was a gift from Wyeth· 
Ayerst Research Laboratories (Princeton. Nn and prepared fresh 
daily by suspension in 0.2% carboxymethyl-ceUulose and thor· 
oughly homogenized before administration. FK 506. provided by 
Fujisawa Pharmaceutical Co (Osaka. Japan). was diluted (with 
carrier solvent HCO-60 and D-mannitol) in normal saline. 
Survival was calculated by the life·table method. Comparisons 
of survival were analyzed using the Wilcoxon signed rank test 
with unequal variances. Two-tailed P values <.05 were consid-
ered statistically significant. 
Study Design 
Animals sulfering from GVHD were treated with CyA, RAP, or 
FK 506 1M on days 12 to 2S post-BMSYIX. Group I was used as 
irradiation control and received 1000 rad TBI without bone 
marrow rescue. Group 2 received BMSYIX without immunosup-
pressive therapy. The remaining groups received BMSPI'X and 
treatment on days 12 to 2S postrCCOnstitution with CyA at 
25/mglkg per day (group 3). RAP at I mglkg per day (group 4). and 
FK 506 at I mglkg per day (group S). The follow-up was 60 days 
post-BMSYIX. Each group consisted of 7 to 10 animals. 
RESULTS 
Recovery From GVHD 
Acute GVHD was induced in recipients of allogeneic 
BMSPTX at a median day of 11 in the range of days 8 to 12. 
eyA, given at 2S mglkg per day aI\ddays 12 to 2S (group 3), 
was able to reverse GVHD in 55% of treated animals. The 
remaining rats failed to recover from GVHD and died 
during or after therapy. All animals (100%) receiving FK 
506 at 1 mglkg per day on days 12 to 25 were rescued. [n 
contrast, treatment with RPM was ineffective in reversing 
GVHD. All animals died displaying signs of GVHD. 
Survival From GVHD 
Survival during and after immunosuppressive therapy is 
presented in Table 1. Irradiation controls receiving only 
TBI died within 16 days. Survival of RPM-treated rats 
(MST = 21.6 :t 5.0) wa.s similar' to that of untreated 
controls (MST = 22.1 :t 4.0). Survival of CyA-treated 
animals (MST = 29.2 :t 12.4) was prolonged compared to 
untreated controls (not statistically significant. P > .15). 
Only the FK 506-treated group (MST = 56.3 :t 4.1) 
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FIg 1. Survival from acute GVHD of allogeneic BMSP recipien1s 
treated with CyA, RPM, or FK 506. Anima.ls received either CyA at 
25 mglkg per day (eyA 25), RPM at 1.0 mglkg per day (RPM 1.0), 
or FK 506 at 1.0 mglkg per day (FK 1.0) on days 12 to 25 
post-BMSPTX. Included are untreated recipients of BMSP (untr 
8M) and irradiation controls (1000 TBI). Data represents survival 
for 7 to 10 animals in each group. 
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EFFECTS OF CvA. RAPAMYCIN. AND FK 506 
showed significant prolongation of survival when com-
pared to untreated controls (P < .01). 
DISCUSSION 
Cy A and FK 506 have been shown to be effective in 
reversing acute GVHD in 55% and 100%. respectively. of 
treated rats following allogeneic BMSPTX. In Cy A-treated 
rats. death during therapy was associated with the pres-
ence of clinical signs of GVHD. In contrast. RAP was 
ineffective in reversing G VHD and rats died maintaining 
GVHD. Recurrence of GVHD after cessation of immuno-
suppressive therapy was responsible for subsequent death 
of both Cy A and FK 506-treated animals. 
Both CyA and FK 506 have been reponed to interfere 
with the activation of T cells. Both drugs suppress the 
release of IL-2 and the expression of the IL.receptor .•. 5 
RPM has little or no effect on these events. but inhibits the 
---- response to IL·2.6 Why CyA and. in particular. FK 506 
and not RPM. are effective in this model long after 
, 
! ~ 
I -'" I: 
3233 
immunologic activation' starts. remains speculative and 
needs further investigation. Nevertheless. a similar effect 
of FK 506 has been shown in human organ transplantation 
where the drug was able to rescue patients experiencing 
rejection episodes of liver grafts despite prior treatment 
with CyA. OK'D. and corticosteroids. 7 
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